Top Story

FDA approves first biosimilar product

March 6, 2015

The FDA today announced the approval of filgrastim-sndz, the first biosimilar product approved in the United States.

“Biosimilars will provide access to important therapies for patients who need them,” Margaret A. Hamburg, MD, FDA commissioner, said in a press release. “Patients and the health care community can be confident that biosimilar products approved by the FDA meet the agency’s rigorous safety, efficacy and quality standards.”

In the Journals

Hospital type, patient age influence treatment of newly diagnosed myelodysplastic syndrome

March 6, 2015
Patients treated for recently diagnosed myelodysplastic syndrome at major academic institutions received more aggressive treatment than those treated at community…
Guido Marcucci, MD Institution Notes

Physician-researcher joins City of Hope

March 5, 2015
Guido Marcucci, MD, a renowned physician and researcher, has accepted a leadership appointment at City of Hope’s new Hematologic Malignancies and Stem Cell…

Bortezomib-based therapy improves outcomes, increases toxicity in mantle cell lymphoma

March 4, 2015
The substitution of bortezomib for vincristine in front-line therapy for mantle cell lymphoma was associated with prolonged PFS and higher response rates, according to…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
FDA approvalsDrug Pipeline

FDA approves first biosimilar product

March 6, 2015
The FDA today announced the approval of filgrastim-sndz, the first biosimilar product approved in the United States.“Biosimilars will provide…
In the Journals

Hospital type, patient age influence treatment of newly diagnosed myelodysplastic syndrome

March 6, 2015
Patients treated for recently diagnosed myelodysplastic syndrome at major academic institutions received more aggressive treatment than those treated…
Guido Marcucci, MD Institution Notes

Physician-researcher joins City of Hope

March 5, 2015
Guido Marcucci, MD, a renowned physician and researcher, has accepted a leadership appointment at City of Hope’s new Hematologic Malignancies…

Bortezomib-based therapy improves outcomes, increases toxicity in mantle cell lymphoma

March 4, 2015
The substitution of bortezomib for vincristine in front-line therapy for mantle cell lymphoma was associated with prolonged PFS and higher response…
FDA NewsDrug Pipeline

FDA grants breakthrough status to EBV-CTL for EBV-associated lymphoproliferative disease

March 2, 2015
The FDA today granted breakthrough therapy designation to EBV-CTL for the treatment of patients with rituximab-refractory, Epstein-Barr…
Deepa Bhojwani, MD Institution Notes

Childrens hospital appoints leukemia director

March 1, 2015
Deepa Bhojwani, MD, has been appointed director of the leukemia/lymphoma program at the Children’s Center for Cancer and Blood Diseases, part…
Barbara Pro, MD In the Journals

PET scans improve response assessment in peripheral T-cell lymphoma

February 26, 2015
Use of 18fluoro-deoxyglucose PET scans more accurately predicted response durability than conventional radiology in patients with relapsed or…
Meir Wetzler Industry News

Leukemia chief at Roswell Park Cancer Institute dies from injuries sustained in ski accident

February 24, 2015
Meir Wetzler, MD, FACP, chief of the Leukemia Section at Roswell Park Cancer Institute, died Feb. 23 of injuries sustained in a skiing accident…
FDA approvalsDrug Pipeline

FDA approves Farydak for multiple myeloma

February 23, 2015
The FDA today announced the approval of panobinostat for the treatment of multiple myeloma.Panobinostat (Farydak, Novartis Pharmaceuticals) is the…
FDA NewsDrug PipelinePerspective

FDA expands approval of Revlimid for newly diagnosed multiple myeloma

February 18, 2015
The FDA today expanded the existing indication of lenalidomide plus dexamethasone to include patients with newly diagnosed multiple myeloma…
More Headlines »
morganatic-roan
morganatic-roan